本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Nautilus Biotechnolgy, Inc.

0.6884
-0.0246-3.45%
盘后0.68890.0005+0.07%19:48 EDT
成交量:27.63万
成交额:19.03万
市值:8,684.06万
市盈率:-1.22
高:0.7119
开:0.7044
低:0.6650
收:0.7130
数据加载中...
2021/08/10

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/08/10

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/08/10

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/08/03

SEC问询函

CORRESP [Cover] - Correspondence
2021/07/22

招股说明书

S-1 - General form for registration of securities under the Securities Act of 1933
2021/06/30

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/06/21

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/06/16

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/06/16

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/06/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/06/10

重要事件披露

8-K - Current report
2021/06/08

企业合并公告

425 - Prospectuses and communications, business combinations
2021/06/08

重要事件披露

8-K - Current report
2021/06/01

重要事件披露

8-K - Current report
2021/06/01

企业合并公告

425 - Prospectuses and communications, business combinations
2021/05/13

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/05/12

SEC问询函

CORRESP [Cover] - Correspondence
2021/05/10

SEC问询函

CORRESP [Cover] - Correspondence
2021/04/23

SEC问询函

CORRESP [Cover] - Correspondence
2021/04/07

企业合并公告

425 - Prospectuses and communications, business combinations